AbbVie Inc. and OSE Immunotherapeutics SA have entered into a strategic partnership to develop OSE-230, a monoclonal antibody designed to target chronic and severe inflammation. This collaboration aims to improve the standard of care for patients worldwide suffering from inflammatory diseases. Under the agreement, AbbVie will have exclusive rights to develop, manufacture, and commercialize OSE-230, with OSE Immunotherapeutics receiving an upfront payment of $48 million and potential milestone payments of up to $665 million.
OSE-230 is a first-in-class monoclonal antibody that activates ChemR23, a G-Protein Coupled Receptor (GPCR) target, offering a novel mechanism for resolving chronic inflammation by modulating the functions of macrophages and neutrophils. By leveraging AbbVie’s expertise in immunology drug development, the companies aim to advance OSE-230 to provide innovative treatment options for patients.
“We are very pleased to collaborate with AbbVie, a global leader in the development and commercialization of innovative medicines, to drive our OSE-230 program forward,” said Nicolas Poirier, CEO of OSE Immunotherapeutics. This partnership marks a significant milestone for OSE Immunotherapeutics, recognizing the value of their R&D capabilities and innovative pipeline.
In addition to the financial aspects of the partnership, OSE Immunotherapeutics will be eligible to receive potential tiered royalties on global net sales of OSE-230, further highlighting the company’s commitment to delivering impactful immunotherapies. The transaction is subject to customary closing conditions and regulatory approvals.
AbbVie’s mission is to discover and deliver innovative medicines that address critical health issues and improve patient outcomes. Through its focus on key therapeutic areas like immunology, oncology, neuroscience, and eye care, AbbVie strives to have a positive impact on people’s lives. For more information about AbbVie, visit http://www.abbvie.com and follow @abbvie on social media platforms.
OSE Immunotherapeutics is dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I). With a well-balanced clinical pipeline that includes innovative therapies like Tedopi® and OR-279, the company aims to advance the field of immunotherapy. OSE Immunotherapeutics expects to generate significant value from its drug discovery platforms focused on inflammation resolution, myeloid checkpoints, and cytokine delivery in IO and I&I.
Overall, the collaboration between AbbVie and OSE Immunotherapeutics represents a promising opportunity to advance the development of OSE-230 and provide much-needed treatment options for patients with chronic inflammation. As the companies work together to bring this innovative monoclonal antibody to market, the future looks bright for those impacted by inflammatory diseases.
Source link